CG Oncology (CGON) Change in Accured Expenses (2023 - 2026)

CG Oncology has reported Change in Accured Expenses for 4 years, with the latest figure at $1.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 92.22% year-over-year to $1.6 million; the trailing twelve-month figure through Mar 2026 stood at $9.4 million (down 9.63% YoY), and the FY2025 full-year result was $8.7 million, up 58.28% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $1.6 million, down from $3.7 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $7.5 million in Q2 2025, with the low at -$4.1 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged $1.5 million across 4 years, with a median of $1.6 million in 2026.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses plunged 2712.03% — and 2025, when it soared 263.53%.
• CG Oncology's Change in Accured Expenses stood at $1.8 million in 2023, then jumped by 89.98% to $3.3 million in 2024, then rose by 11.77% to $3.7 million in 2025, then plunged by 56.93% to $1.6 million in 2026.
• The last three Change in Accured Expenses figures came in at $1.6 million (Q1 2026), $3.7 million (Q4 2025), and -$3.4 million (Q3 2025), per Business Quant data.